Urogen Pharma (NASDAQ:URGN – Get Free Report) and Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings and dividends.
Institutional & Insider Ownership
91.3% of Urogen Pharma shares are held by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are held by institutional investors. 4.8% of Urogen Pharma shares are held by insiders. Comparatively, 9.5% of Gyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Urogen Pharma and Gyre Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Urogen Pharma | $188.73 million | 11.04 | -$153.49 million | ($1.98) | -21.54 |
| Gyre Therapeutics | $109.82 million | 6.79 | $5.03 million | ($0.21) | -31.86 |
Gyre Therapeutics has lower revenue, but higher earnings than Urogen Pharma. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Urogen Pharma, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for Urogen Pharma and Gyre Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Urogen Pharma | 1 | 1 | 8 | 0 | 2.70 |
| Gyre Therapeutics | 2 | 0 | 1 | 0 | 1.67 |
Urogen Pharma currently has a consensus price target of $52.38, suggesting a potential upside of 22.83%. Gyre Therapeutics has a consensus price target of $16.00, suggesting a potential upside of 139.16%. Given Gyre Therapeutics’ higher possible upside, analysts clearly believe Gyre Therapeutics is more favorable than Urogen Pharma.
Profitability
This table compares Urogen Pharma and Gyre Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Urogen Pharma | -51.73% | N/A | -43.79% |
| Gyre Therapeutics | -15.47% | -6.57% | -5.35% |
Volatility and Risk
Urogen Pharma has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500. Comparatively, Gyre Therapeutics has a beta of 1.92, indicating that its share price is 92% more volatile than the S&P 500.
About Urogen Pharma
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
About Gyre Therapeutics
Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
